Eamonn Cooney has retired and stepped down as BABA's President
Dear Members and Colleagues,
After a truly interesting, sometimes crazy but lucky global career over many decades, I am retiring! So, I will step down as President on March 31, 2021, BABA’s year-end.
Having lived in 5 countries, I have been fortunate to have carried out business in over 40 countries across the globe, at the highest levels, working with Government Ministers, Ambassadors, High Commissioners, key NGO’s, CEO’s and other Industry leaders.
Certainly a highpoint of this career has been my years with BABA, from joining the Board in 2007, to becoming Chairman of the DATS Committee, Vice President, and finally, as President for the last 5 years.
It has been a privilege to serve you as President, working with so many wonderful colleagues inside and outside BABA, especially BABA’s leadership and all those at the British Embassy, in support of UK-US trade and investment.
As I move on, BABA is a strong business association with an excellent and prestigious membership. Amongst all I got to do in BABA, the best was managing and providing key benefits to all our members. Especially such a wide range of business and social events, building and working closely with our excellent Committees and Groups, enhancing membership and launching our private Members' Directory, to example just some of this rewarding work.
Naturally, my best memories are from getting to know so many of you so well and attending all those excellent events over the last 17 years. Most recently was our unique 2020 Christmas Gala Party, BABA’s first hybrid live-streamed and virtual event. This was a special fun experience and success, so it is a high point on which to retire!
I planned to retire last year, but stayed to oversee BABA’s smooth transition to virtual operations and events. So as a Past-President, I will look forward to remaining a member, attending events, (especially when back in-person!) and supporting BABA.
The British-American Business Association
February 19th, 2021
AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “As COVID-19 continues its grip on the world, the need for a vaccine to defeat the virus is urgent. This collaboration brings together the University of Oxford’s world-class expertise in vaccinology and AstraZeneca’s global development, manufacturing and distribution capabilities. Our hope is that, by joining forces, we can accelerate the globalisation of a vaccine to combat the virus and protect people from the deadliest pandemic in a generation.”
The potential vaccine entered Phase I clinical trials last week to study safety and efficacy in healthy volunteers aged 18 to 55 years, across five trial centres in Southern England. Data from the Phase I trial could be available next month. Advancement to late-stage trials should take place by the middle of this year. Read full article.